Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eldelumab in active ulcerative colitis
NCT00656890Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2008
- Primary completion
- Sep 2009
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in ulcerative colitis (UC) comparing MDX-1100 with Placebo (2 arms). Primary endpoint: Change in Mayo score at Day 57 compared with Screening. Started Apr 2008; status: completed.
02
Drugs
eldelumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00656890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00656890.